Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Abstract 994: Advancing health equity and reducing disparities in prostate cancer in Black men: iCCaRE
Bonner, Timethia , Cobran, Ewan K. , Odedina, Folakemi T., Merriweather, AJ, Kaninjing, Ernie, Willis, Floyd B. , Moore, Cassandra N., Oliver, Joanne, Bedell, Fornati, Ashing, Kimlin , Kaninjing, Ernie, McCall, John

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 994-994

10.1158/1538-7445.am2025-994 Get It

Abstract In the US and globally, Black men experience the highest prostate cancer burden among all racial and ethnic groups, underscoring the urgent need for research to guide the development and implementation of culturally tailored strategies aimed at reducing disparities and improving outcomes. In response, the Inclusive Cancer Care Research Equity (iCCaRE) Consortium was created to advance health equity and reduce disparities in prostate cancer. Importantly, a Survivorship Care Plan (SCP) is recommended to educate and empower patients, enabling them to be better informed about their cancer diagnosis, treatment, and survivorship care recommendations. To date, there is no SCP targeted to Black prostate cancer survivors (CaPS) who have the greatest disparities with the poorest survivorship outcomes (ACS F&F; AACR HD Report; Fullwood, 2024). Therefore, we aimed to develop a SCP tailored for Black men. Addressing the unique needs of Black men require a genuine bidirectional relationship between scientist and the community rooted in community engaged research (CER). The SCP was first informed by the literature (Bonner, 2024) and the ASCO template (canceradvocacy.org). With input from the iCCaRE leadership and the Partnership Engagement Services (PES) Core, the Whole Person SCP better responds to the informational, clinical and quality of life needs of Black Prostate Cancer survivors. Based on CER, we included 22 diverse, Black CaPs to further guide and tailor the iCCaRE. Our findings indicate that the iCCaRE Survivorship Care Plan (SCP) enhanced the ASCO template by incorporating and expanding several unique domains, including family history, care team contacts, follow-up and surveillance, symptoms, quality of life, survivor concerns, major comorbidities, health advisories, and culturally relevant resources, creating a comprehensive, whole-person SCP tailored specifically for Black men. It is crucial to continue to improve support for clinical research and advocate for Black men and their communities to reduce prostate cancer burden. Prostate cancer also needs to include incidence, mortality, and disparities for Black men to raise awareness of scarcely studied field of Black men and prostate cancer survivorship. Citation Format: Kimlin Tam Ashing, Timethia Bonner, Ewan K. Cobran, Folakemi Odedina, Aj Merriweather, Ernie Kaninjing, Floyd Willis, Cassandra Moore, Joanne Oliver, Fornati Bedell, John McCall. Advancing health equity and reducing disparities in prostate cancer in Black men: iCCaRE [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 994.
Abstract 2763: Molecular QTL analyses identify functional variants at inherited risk loci in chronic lymphocytic leukemia
Yan, Huihuang , Hoel, Mingma , Allmer, Cristine, McCabe, Chantal E. , O’Brien, Daniel , Robinson, Dennis H., Wang, Zhiquan , Robinson, Dennis, Cerhan, James R. , Parikh, Sameer A. , Braggio, Esteban , Slager, Susan L.

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2763-2763

10.1158/1538-7445.am2025-2763 Get It

Abstract Most disease-associated single-nucleotide polymorphisms (SNPs) identified by genome-wide association studies (GWASs) reside in noncoding regions. There is increasing evidence that they play regulatory roles through epigenetic mechanisms by altering local chromatin state, 3D chromatin structure, and looping interactions. We and others have identified 42 CLL risk loci from GWASs. At 12 risk loci located outside of gene promoters, we previously demonstrated that functional SNPs are highly enriched in enhancers and super-enhancers that mostly target BCL2 family genes and transcriptional regulators. However, the study was limited by using only public epigenomic data generated in lymphoblastoid cell lines (LCL) and normal immune related cell types. To gain a better understanding of how the functional SNPs alter local chromatin state and modulate target gene expression in CLL, we generated RNA-seq data (n=588) and transposase-accessible chromatin with sequencing (ATAC-seq) data (n=69) in CLL tumor B cells. We performed molecular quantitative trait loci (QTL) analysis with index and correlated SNPs (R2 0.5) at 41 risk loci (excluding the HLA locus). The analyses identified cis expression QTLs (eQTLs), within 1Mb of genes’ transcription start site, at 25 risk loci and chromatin accessibility QTLs (caQTLs, within peak) at 11 risk loci, with both eQTLs and caQTLs at 8 risk loci. We identified a total of 54 eGenes, for which the expression is affected by nearby SNPs within 1Mb, including 40 novel eGenes at 16 CLL risk loci not previously reported. Notably, based on publicly available chromosome interaction data from CLL, LCL, and normal B cells, for over 70% of the novel eGenes, their promoters showed looping interactions with the regions carrying the eQTLs. Further, 13 SNPs were identified as both caQTL and eQTL, with the associated novel eGenes including CD81 at 11p15.5, IPCEF1 at 6q25.2, as well as CXXC1 and MBD1 at 18q21.1. The result suggests that these SNPs play a role in altering chromatin accessibility contributed to gene expression variation. At 11p15.5 risk locus, SNP rs2651823 (A/G) represents a novel caQTL and eQTL. The alternative G allele is associated with increased chromatin accessibility and CD81 expression. Hi-C data from GM12878 and CD20+ B cells supported interaction between the open chromatin region carrying rs2651823 and CD81 promoter. CD81 facilitates the trafficking of CD19 to the surface of activated B cells, and CD81-null mice showed impaired immune response. In a mouse model, CD81 contributes to tumor progression and metastasis in Lewis lung carcinoma. In summary, our molecular QTL analysis revealed that functional SNPs, located in CLL risk loci, modulate chromatin accessibility and expression of downstream target genes that could impact CLL risk. Citation Format: Huihuang Yan, Zhiquan Wang, Mingma Hoel, Cristine Allmer, Chantal McCabe, Daniel O’Brien, Dennis Robinson, James Cerhan, Sameer Parikh, Esteban Braggio, Susan Slager. Molecular QTL analyses identify functional variants at inherited risk loci in chronic lymphocytic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2763.
Abstract 166: Spatial subtypes and cellular interactions of cancer-associated fibroblasts revealed by single-cell spatial omics
Zhang, Yuanyuan , Liu, Yang , Wang, Ruiping , Pei, Guangsheng , Cho, Kyung Serk , Basi, Akshay , Rajapakshe, Kimal , Chu, Yanshuo , Jiang, Jiahui , Zhang, Daiwei , Yan, Xinmiao , Guerrero, Paola A. , Li, Mingyao , Hwang, Tae Hyun , Futreal, P. Andrew , Soto, Luisa M. Solis , Kadara, Humam , Liu, Yunhe , Sinjab, Ansam F. , Min, Jimin , Han, Guangchun , Paradiso, Francesca , Dai, Enyu , Burks, Jared K , Serrano, Alejandra G. , Ajani, Jaffer A. , Jazaeri, Amir Anthony , Maitra, Anirban , Wang, Linghua

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 166-166

10.1158/1538-7445.am2025-166 Get It

Abstract Background: Cancer-associated fibroblasts (CAFs) are a highly diverse cell population that plays a crucial role in shaping the tumor microenvironment (TME). Their spatial interactions within the TME remain to be systematically characterized, and the factors driving their phenotypic heterogeneity are not yet fully understood. Recent advancements in single-cell spatial transcriptomics technologies and cell segmentation approaches enable the precise measurement of thousands of transcripts at subcellular resolution. Combined with innovative bioinformatics, these advancements have unlocked unprecedented opportunities for in-depth characterization of CAFs and their interactions within the TME. Methods: We conducted a comprehensive spatial transcriptomic analysis of CAFs across 8 cancer types, using the CosMx and MERSCOPE platforms to profile nearly 6 million cells as part of our discovery cohorts. We developed a novel computational method to spatially cluster CAF subpopulations and defined four distinct spatial CAF subtypes. We further examined their phenotypic differences, spatial niche organization, and interactions with neighboring cells. Additionally, we investigated the influence of CAF subtypes on immune cell phenotypes and infiltration levels. To validate our findings, we employed multiple spatial platforms, including Visium, Xenium, COMET, CODEX, and IMC, to ensure reproducibility across diverse technologies. Moreover, we performed correlative studies in large-cohorts with rich clinical data to evaluate the clinical significance of these CAF subtypes. Results: Our approach provided an unprecedented high-resolution examination of the spatial phenotypes of CAFs in large, complex tissues, uncovering novel insights. We comprehensively characterized CAFs across various solid tumor types and identified four conserved spatial CAF subtypes. These subtypes are characterized by distinct cell organizational patterns, neighboring cell compositions, interaction networks, and transcriptomic features. Moreover, they demonstrate significant correlations with the abundance, distribution, and phenotypes of tumor-infiltrating immune cells, as well as associations with tumor histopathological features and clinical outcomes. Conclusions: Our study provides a pan-cancer, high-resolution characterization of CAF spatial organization and interactions in solid tumors and identified conserved spatial CAF subtypes linked to distinct organizational patterns. Our findings reveal that the transcriptomic states and phenotypes of CAFs are significantly shaped by their interactions with neighboring cancer and immune cells. Beyond offering novel insights into the spatial heterogeneity of CAFs, this work paves the way for developing strategies to effectively target and modulate CAFs for therapeutic benefit. Citation Format: Yunhe Liu, Ansam Sinjab, Jimin Min, Guangchun Han, Francesca Paradiso, Yuanyuan Zhang, Yang Liu, Ruiping Wang, Guangsheng Pei, Kyung Serk Cho, Enyu Dai, Akshay Basi, Jared K. Burks, Kimal I. Rajapakshe, Yanshuo Chu, Jiahui Jiang, Daiwei Zhang, Xinmiao Yan, Paola A. Guerrero, Alejandra Serrano, Mingyao Li, Tae Hyun Hwang, Andrew Futreal, Jaffer A. Ajani, Luisa M Solis Soto, Amir A. Jazaeri, Humam Kadara, Anirban Maitra, Linghua Wang. Spatial subtypes and cellular interactions of cancer-associated fibroblasts revealed by single-cell spatial omics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 166.
Abstract 1145: Morphological evaluation of chromosomal instability in circulating tumor cells and prediction of taxane resistance in metastatic prostate cancer: a prespecified sub-analysis of the CARD trial
Longoria, Ossian , Beije, Nick , Efstathiou, Eleni, Castellano, Daniel , Fizazi, Karim , Sharp, Adam , Macé, Sandrine , Geffriaud-Ricouard, Christine, Wenstrup, Richard , Wit, Ronald de , Bono, Johann S. de , de Bono, Johann , Rekowski, Jan , Gupta, Santosh , Pantel, Klaus , Sternberg, Cora N , Tombal, Bertrand , Sartor, Oliver

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1145-1145

10.1158/1538-7445.am2025-1145 Get It

Abstract Background: Chromosomal instability (CIN) is frequent in patients with metastatic castration-resistant prostate cancer (mCRPC) and determines taxane resistance. A circulating tumor cell (CTC) assay which morphologically identifies CTCs with CIN (CTC-CIN) from a single tube of whole blood could predict clinical outcomes in this population. We tested this hypothesis as a pre-planned, secondary outcome of the CARD trial, where patients with mCRPC progressing within a year of treatment with an androgen receptor pathway inhibitor (ARPI; enzalutamide or abiraterone acetate + prednisolone/prednisone) were randomized to treatment with cabazitaxel or the alternative ARPI. Methods: CTCs were isolated from blood samples obtained at baseline; cycle two, and end of treatment. The associations of baseline CTC and counts with imaging-based progression free survival (ibPFS), overall survival (OS), time to prostate-specific antigen (PSA) progression, RECIST 1.1 objective response rate (ORR), and PSA50 response rate (PRR) were assessed. Results: Of 255 patients randomized, CTC counts were acquired from 237 patients at screening, 213 patients at C2D1, and 166 patients at EOT. High baseline CTC counts were significantly associated with worse OS (median OS, 14.9 vs 9.8 months; univariate HR, 1.81; 95% CI, 1.30 - 2.51; p < 0.001). High baseline CTC-CIN counts were significantly associated with worse OS after adjustment for confounding variables (median OS, 15.3 vs 8.9 months; univariate HR, 2.16; 95% CI, 1.52 - 3.06; p < 0.001; multivariate HR, 1.56; 95% CI, 1.01 - 2.43; p = 0.047). Low CTC-CIN at baseline predicted ibPFS, ORR, and PRR benefit with cabazitaxel; conversely, high at baseline predicted no different ibPFS or OS outcomes with cabazitaxel or a second ARPI. Conclusions: This preplanned biomarker analysis of CARD confirmed that CTC-CIN counts are prognostic for OS and may be predictive of cabazitaxel benefit. (Funded by Sanofi and Epic Sciences; CARD ClinicalTrials.gov number, NCT02485691.) Citation Format: Ossian Longoria, Jan Rekowski, Santosh Gupta, Nick Beije, Klaus Pantel, Eleni Efstathiou, Cora Sternberg, Daniel Castellano, Karim Fizazi, Bertrand Tombal, Adam Sharp, Oliver Sartor, Sandrine Mace, Christine Geffriaud-Ricouard, Richard Wenstrup, Ronald de Wit, Johann de Bono. Morphological evaluation of chromosomal instability in circulating tumor cells and prediction of taxane resistance in metastatic prostate cancer: a prespecified sub-analysis of the CARD trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1145
Abstract 1107: Feature selection and machine learning strategies optimize an affordable molecular assay for cholangiocarcinoma subtype
Jessen, Erik , Carlson, Danielle M. , Salehinejad, Hojjat , Larson, Ellen L. , Mun, Dong‐Gi , Tomlinson, Jennifer L. , Abdelrahman, Amro M. , Carlson, Danielle Marie , Smoot, Rory L.

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1107-1107

10.1158/1538-7445.am2025-1107 Get It

Background: Cholangiocarcinoma is a molecularly heterogenous cancer arising from the biliary epithelium. Individual omic techniques have identified clinically relevant, targetable subtypes but most tumors have no targetable alterations based on exome or transcriptomic evaluation. Integrated multiomics approaches incorporating transcriptomic, proteomic, and phosphoproteomic characterization provide deeper understanding and identify non-mutated, activated pathways that can be targeted. To optimize the potential clinical utility of these approaches, minimal classifier features must be defined. Methods: Approximately 60,000 RNA, protein, and phosphoprotein features were extracted from 35 cholangiocarcinomas treated at the primary US study site. 206 patients treated and profiled at an institution in China were also included. Using the Multiomics Factor Analysis clustering method, patients were sorted into 3 distinct molecular profiles. Important molecular features were selected using competing feature selection (FS) methods: Boruta, RreliefF, variable selection using random forests (RF), recursive factor elimination (RFE), median decrease accuracy in RF, and Concrete Autoencoders. Machine learning classification prediction models including Extreme Gradient Boosting, gradient-boosted trees, multinomial logit, and support vector machine (SVM) were tested on each FS. Each combination of FS and predictive model was tested with 10 replicates of 10-fold cross-validation of a randomly-selected balanced test set and an oversampled, balanced training subset. Accuracy, F1 score, AUC, precision, and recall were assessed for each FS and predictive model combination. A custom function of physical assay cost and classification accuracy was optimized to find the best assay. KEGG pathway overrepresentation analysis was used to analyze feature subsets. Results: A consistent set of 50 important RNA and protein features was identified, including previously reported prognostic factors, like SpryD4 protein expression, as well as previously unreported pathway surrogates, such as Slc2A2 or Pipox protein. Pathway overrepresentation analysis found insulin signaling and resistance and amino acid biosynthesis/metabolism pathways were overrepresented in the discriminative feature set. The gradient-boosted trees algorithm combined with the RFE FS method had the best performance, with a multiclass macro average (±sd) cross-validation accuracy 89% (±6%), F1 score 89% (±8%), AUC 0.98 (±0.02), precision 90% (±10%), recall 89% (±6%). Conclusions: Feature selection methods and predictive machine learning models work synchronously to develop accurate molecular subtype assays based on just 50 protein and RNA levels. This strategy has the potential to make molecular subtyping for cholangiocarcinoma and other molecularly complex cancers fast and widely available. Citation Format: Ellen Larson, Erik Jessen, Dong-Gi Mun, Jennifer Tomlinson, Amro Abdelrahman, Danielle Carlson, Hojjat Salehinejad, Rory Smoot. Feature selection and machine learning strategies optimize an affordable molecular assay for cholangiocarcinoma subtype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1107.
Abstract 519: CDK4/6 inhibitors and endocrine therapies induce senescence with drug- and cell line-specific vulnerabilities in ERα+ breast cancer
Guilatco, Angelo Jose, Detry, Anna, Wang, Xiyin , Weivoda, Megan , Hawse, John R. , Batoon, Lena

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 519-519

10.1158/1538-7445.am2025-519 Get It

Abstract Estrogen receptor alpha (ERα)-positive breast cancer accounts for up to 80% of cases. Despite advances in CDK4/6 inhibitors (CDK4/6i) and endocrine therapies, recurrence and late relapse remain significant challenges. Recurrence often arises from disseminated cancer cells that persist despite 5-10 years of systemic adjuvant treatment. While CDK4/6i and endocrine therapies induce prolonged growth arrest resembling senescence, they do not significantly kill cancer cells. Senescent/pseudo-senescent cancer cells are implicated in aggressive variant formation, recurrence, and metastasis. We explored eliminating breast cancer cells via senolysis while they are in therapy-induced senescent state to prevent their potential to escape, repopulate, or cause long-term adverse effects. Live-cell imaging of MCF7 and T47D cells treated with abemaciclib and endocrine therapies (endoxifen or estrogen deprivation to mimic aromatase inhibition) at clinically relevant concentrations for eight days demonstrated prolonged growth cessation and G1 cell cycle arrest even two weeks post-drug withdrawal. These cells displayed a senescence-like gene expression profile, with increased CDKN2B (p15), CDKN1A (p21), BCL2, reduced KI67, and increased TGFβ expression, a known Senescence-Associated Secretory Phenotype (SASP) factor linked to deep senescence. These results confirm effective senescence induction by various CDK4/6i and endocrine therapy combinations. Further analysis using established senescence markers (e.g., nuclear size, telomere-associated foci, satellite distension, and loss of nuclear HMGB1 and LaminB1) revealed unique senescence phenotypes across therapy combinations. Cell viability assays and live imaging of Caspase 3/7 activation demonstrated differential vulnerabilities of senescent/senescent-like ERα+ cancer cells (MCF7, T47D, UCD4, UCD12) to 13 senolytics (1 μM), including natural flavonoids and inhibitors targeting pro-survival factors, tyrosine kinases, and the Notch pathway. For example, MCF7 and UCD4 cells responded to MCL1i and RSL3, T47D to BCLXLi and RSL3, and UCD12 to BCLXLi and Navitoclax. Notably, senolytic cocktails (e.g., RSL3, GNF7, Venetoclax, Dasatinib) at reduced concentrations (0.25 μM each) effectively eliminated senescent/senescent-like ERα+ cancer cells across all cancer cell lines, achieving 100% elimination in T47D cells. Collectively, these findings demonstrate that despite variability in therapy-induced senescence, senolytic combinations effectively target senescent ERα+ cancer cells. This provides preliminary evidence for the potential integration of this strategy into standard breast cancer therapy with a goal to improve recurrence-free survival and increase the cure rates for ERα+ breast cancer patients. In vivo studies are underway to evaluate this strategy in preclinical models. Citation Format: Lena Batoon, Angelo J. Guilatco, Anna Detry, Xiyin Wang, Megan M. Weivoda, John R. Hawse. CDK4/6 inhibitors and endocrine therapies induce senescence with drug- and cell line-specific vulnerabilities in ERα+ breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 519.
Abstract 765: Spatial transcriptomic profiling of normal breast tissue reveals potential mechanisms underlying increased breast cancer risk in Black women
Erak, Camila Pacheco, Cruz-Reyes, Nicole , Westerman, Pria, Ogony, Joshua, Hwang, Tae Hyun , McLaughlin, Sarah A. , Westerman, Pria, Clemenceau, Jean R. , Radisky, Derek C.

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 765-765

10.1158/1538-7445.am2025-765 Get It

Abstract Purpose: Black women are disproportionately affected by aggressive breast cancers compared to white women, suggesting underlying biological differences in normal breast tissue. This study aims to identify molecular disparities in normal breast tissue between premenopausal Black and white women that may contribute to increased breast cancer risk. Experimental Procedures: Visium spatial transcriptomic analysis was performed on a pilot cohort of normal breast tissue samples from premenopausal Black and white women. Tissue sections were spatially profiled, and capture spots were classified based on predominant cell types: epithelial, stromal, or endothelial. Differential gene expression analysis between racial groups was conducted for each cell type classification. Multiplex immunofluorescence (mIF) was used to validate selected markers in the pilot cohort. Meta-analysis compared differentially expressed genes with published gene sets associated with breast cancer subtypes. Results: Significant racial differences in gene expression profiles were identified in both epithelial and stromal spots. In epithelial spots, genes upregulated in Black women significantly overlapped with over 20 published gene sets associated with estrogen receptor-negative (ER−) breast cancer, including key genes involved in Wnt signaling inhibition (e.g., WIF1) and basal epithelial markers (e.g., KRT14, KRT15). This suggests alterations in pathways linked to more aggressive breast cancer phenotypes. In stromal spots, differentially expressed genes related to extracellular matrix remodeling and fibroblast activation (e.g., PI16, DPT, EFEMP1) were observed, indicating potential differences in stromal-epithelial interactions. Ongoing deconvolution and spatial analyses are being performed to further elucidate these findings. Preliminary mIF validation confirmed increased expression of PI16 in samples from Black women. Validation of additional markers is underway in a larger cohort of premenopausal Black and white women. Conclusions: Spatial transcriptomic profiling of normal breast tissue reveals distinct molecular differences between Black and white women, particularly in pathways associated with aggressive breast cancer subtypes and stromal interactions. These findings suggest that inherent variations in the normal breast microenvironment may contribute to the increased risk and aggressiveness of breast cancer in Black women. Further validation and analysis may identify potential biomarkers for risk assessment and inform targeted prevention strategies. Citation Format: Camila Pacheco Erak, Nicole Cruz-Reyes, Pria Westerman, Joshua Ogony, Jean R. Clemenceau, Tae Hyun Hwang, Sarah McLaughlin, Derek Radisky. Spatial transcriptomic profiling of normal breast tissue reveals potential mechanisms underlying increased breast cancer risk in Black women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 765.
Abstract 940: Harnessing oncolytic virus VSV and combination therapy to advance treatments for relapsed refractory multiple myeloma using Vk*MYC models
Ying, Yi, Zhang, Lianwen , Nace, Rebecca A., Chesi, Marta, Peng, Kah Whye, Ma, Yi Ying, Chesi, Marta

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 940-940

10.1158/1538-7445.am2025-940 Get It

Abstract VSV-IFNβ-NIS (VV1) is a Vesicular Stomatitis Virus (VSV) that encodes the interferon beta (IFNβ) and the iodide symporter (NIS) gene. The IFNβ gene confers tumor selectivity and enhances host antitumor immunity while the NIS gene acts as an imaging biomarker, allowing noninvasive imaging of viral infection sites using PET/SPECT. Multiple myeloma (MM) is a cancer of plasma cells and poses a challenge for treatment due to its biological heterogeneity. As MM usually relapses and is refractory, current therapies face the issue of drug resistance and patients may have to turn to novel therapies. Therefore, we set out to understand the activity of VSV which could be a new approach for patients with relapsed refractory MM (RRMM). Our study utilized two unique bortezomib resistant Vk*MYC transplantable models, Vk12598 and Vk12653, with distinct genomic features. Upon re-transplantation of splenocytes from these mice, flow cytometry revealed that Vk12598 and Vk12653 mice had high MM populations in the spleen and bone marrow. To assess VV1 efficacy in tumor bearing mice, we performed a VV1 dose escalation study, showing efficacy in delaying MM development and prolonging survival in both mice models, with Vk12598 being the more responsive model. Later studies also showed that VV1 induces tumor remission in the Vk12598 model when treatment was initiated at low tumor burden (gamma/albumin ratio ∼0.2). IFNβ levels increased significantly post 24-72h of VV1 treatment, indicating targeted infection and replication of the virus in MM cells. However, high doses of VV1 led to toxicity, as observed from early mortality and weight loss. To determine the sites of MM metastasis and VV1 infection, timepoint harvests were carried out. Hematoxylin and eosin and immunostainings showed the onset of MM of Vk*MYC in the bone marrow and spleen first, then later in the liver. Immunofluorescent staining confirmed that the higher the tumor burden observed, the more VV1 was present in the tissues. To enhance VV1 efficacy, we performed in vivo combination therapies of VV1 with anti-PD-1, an inhibitor of PD-1 which is overexpressed on MM patient T cells; and bortezomib, which inhibits NF-κB which in turn prevents IFN pathway protein transcription, potentially enhancing the replication of VV1 virus. In Vk12598 mice, VV1 combined with both drugs induced tumor regression and doubled the median survival time compared to treatment with VV1 only or VV1 coupled with either of the drugs individually. Addition of VV1 to either anti-PD-1 or bortezomib alone also increased survival time significantly. Studies are still ongoing to understand the mechanisms of VSV and its combination treatments in Vk*MYC models. This translational study will allow us to gain the knowledge needed to refine VSV treatments and provide novel therapy combinations to improve MM patient survival. Citation Format: Yi Ying Ma, Lianwen Zhang, Rebecca A. Nace, Marta Chesi, Stephen J. Russell, Kah Whye Peng. Harnessing oncolytic virus VSV and combination therapy to advance treatments for relapsed refractory multiple myeloma using Vk*MYC models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 940.
Abstract 187: STAT1 and GBP1 promote proliferation in postpartum breast epithelium by downregulating cyclin-dependent kinase inhibitors: implications for increased postpartum breast cancer risk
Ogony, Joshua, McLaughlin, Sarah A. , Sherman, Mark E. , Stallings‐Mann, Melody , Radisky, Derek C.

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 187-187

10.1158/1538-7445.am2025-187 Get It

Abstract Background: Postpartum breast cancer (PPBC) is associated with increased morbidity and mortality among women within 5 to 10 years following childbirth. The postpartum breast undergoes involution, involving tissue remodeling and immune cell infiltration, potentially creating a pro-tumorigenic microenvironment. The molecular mechanisms underlying this elevated risk remain poorly understood. In this study, we compared normal breast tissue samples and human mammary epithelial cells (HMECs) from postpartum women to those from age- and BMI-matched nulliparous women to elucidate potential molecular contributors to PPBC risk. Methods: Transcriptomic profiling was performed on RNA extracted from FFPE normal breast tissues using the NanoString IO 360 and BC 360 platforms to examine gene expression in nulliparous and postpartum women under 45 years of age. HMECs were isolated from organoids derived from breast tissue samples and used for next-generation sequencing and knockdown experiments targeting STAT1 and GBP1. Gene set enrichment analysis (GSEA) was applied to NanoString and RNA-seq datasets to identify differentially enriched genes between postpartum and nulliparous women. Results: Transcriptomic analysis revealed significant upregulation of interferon-stimulated genes, including STAT1 and GBP1, in postpartum breast tissues, consistent with increased immune responses during involution. NanoString data showed that markers of cell proliferation, such as Ki67, STAT1, and GBP1, were significantly higher in samples from parous compared to nulliparous women (p < 0.05). GSEA revealed that cell cycle-promoting genes (GBP1, cyclins, CDKs) were upregulated, while cyclin-dependent kinase inhibitors (CDKNs) were downregulated in postpartum breast tissues. Immunohistochemistry confirmed significantly higher expression of Ki67, STAT1, and GBP1 in postpartum versus nulliparous breast tissues (p < 0.0001). Silencing STAT1 and GBP1 in HMECs resulted in decreased cell proliferation, G1 cell cycle arrest, and increased expression of CDKN1A and CDKN1C. Conclusion: These findings suggest that STAT1 and GBP1 promote proliferation in postpartum breast epithelial cells by downregulating cyclin-dependent kinase inhibitors, potentially contributing to the increased risk of PPBC. Targeting these pathways may offer novel strategies for mitigating postpartum breast cancer risk. Citation Format: Joshua Ogony, Melody Stallings-Mann, Sarah McLaughlin, Mark Sherman, Derek C. Radisky. STAT1 and GBP1 promote proliferation in postpartum breast epithelium by downregulating cyclin-dependent kinase inhibitors: implications for increased postpartum breast cancer risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 187.
Abstract 574: Detection of tumor cell surface calreticulin after doxorubicin treatment using a novel radiolabeled nanobody
Guenter, Rachael , Golivi, Yuvasri, Hall, Lucinda , Prairie, Chloe La, Miller, Caleb, Carlson, Danielle M. , Truty, Mark J. , Larimer, Benjamin M. , Abdelrahman, Amro, Rao, Tejeshwar C. , Carlson, Danielle Marie , Rose, John Bart

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 574-574

10.1158/1538-7445.am2025-574 Get It

Abstract Background: Targeted agents, such as nanobodies, can be covalently linked to radionuclide chelators for theranostics. Nanobodies are single-domain immunoglobulin variable regions with a short blood half-lives and high specificity. Calreticulin (CALR) is endoplasmic reticular (ER) protein that translocates to the cell surface upon induction with certain agents, namely doxorubicin. We hypothesized surface CALR on tumors could be targeted using a novel nanobody after induction with doxorubicin. Methods: Studies were conducted using in vitro and in vivo models of pancreatic ductal adenocarcinoma (PDAC). Surface CALR expression was determined by western blot on fractionated lysates, flow cytometry, or immunofluorescence (IF). Doxorubicin was administered by intraperitoneal injection to mouse models of PDAC. The anti-CALR nanobody was developed via the panning of a synthetic nanobody phage display library. The top CALR-binding nanobody was confirmed by ELISA, immunohistochemistry (IHC), and flow cytometry. For in vivo studies, the nanobody was conjugated with the chelator NOTA and radiolabeled with 64Cu. PET images were acquired 1-hour after injection. Significance was determined using an independent t-test and p values < 0.05 were considered statistically significant. Results: PDAC cells treated with doxorubicin showed peak surface CALR expression between 24 and 48 hours. Flow cytometry revealed that 61.7% of live PDAC cultured cells treated for 24 hours expressed surface CALR, compared to 2.2% in controls (p < 0.001). In a subcutaneous syngeneic PDAC mouse model, two doses of doxorubicin 48 hours apart significantly increased surface CALR, with 30.4% of live-cells expressing CALR in treated tumors versus 1.5% in controls (p < 0.001). Similarly, doxorubicin-treated tumors from a PDAC patient derived xenograft (PDX) model had a 6.7-fold increase in live-cells expressing surface CALR compared to controls (p < 0.01). IF confirmed a 1.4-fold increase in CALR expression in doxorubicin-treated tumors from the subcutaneous PDAC mouse model (p < 0.01) and a 1.7-fold increase in the PDAC PDX model (p < 0.01). Our anti-CALR nanobody has an apparent 37 nM affinity for recombinant CALR and successfully detected surface CALR by IHC and flow cytometry. In vivo PET imaging showed significant increased uptake of the 64Cu-NOTA-nanobody in tumors from doxorubicin-treated mice over controls, with no significant changes in heart, kidney, or liver accumulation by PET quantification and flow cytometry (p < 0.05). Conclusions: Systemic doxorubicin treatment induces CALR surface translocation in tumors that can be successfully targeted with a radiolabeled nanobody for PET imaging. Targeting chemotherapy-induced surface CALR using our radiolabeled nanobody could provide a theragnostic strategy for the detection and treatment of PDAC. Citation Format: Rachael Guenter, Yuvasri Golivi, Lucinda Hall, Amro Abdelrahman, Chloe La Prairie, Caleb Miller, Tejeshwar C. Rao, Danielle M. Carlson, Mark J. Truty, Benjamin Larimer, J. Bart Rose. Detection of tumor cell surface calreticulin after doxorubicin treatment using a novel radiolabeled nanobody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 574.